Changes in the molecular profiles of large-vessel vasculitis treated with biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors

• Published in: Frontiers in immunology Vol. 14; p. 1197342
• Main Authors: Matsumoto, Kotaro, Suzuki, Katsuya, Takeshita, Masaru, Takeuchi, Tsutomu, Kaneko, Yuko
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 01.05.2023
• Subjects: Animals; Antirheumatic Agents - pharmacology; Antirheumatic Agents - therapeutic use; biological disease-modifying anti-rheumatic drugs; giant cell arteritis; Giant Cell Arteritis - drug therapy; Immunology; janus kinase inhibitors; Janus Kinase Inhibitors - pharmacology; Janus Kinase Inhibitors - therapeutic use; Mice; molecular remission; Recurrence; takayasu arteritis; Takayasu Arteritis - drug therapy; biological disease-modifying anti-rheumatic drugs; giant cell arteritis; janus kinase inhibitors; molecular remission; takayasu arteritis

Giant cell arteritis and Takayasu arteritis are two types of primary large-vessel vasculitis (LVV). Although glucocorticoids (GC) are the standard treatment for LVV, the disease relapse rates are high. Recent clinical trials on biological disease-modifying anti-rheumatic drugs (bDMARDs) and Janus ki...